Henneberry, Erin
Lamy, Martine
Dominick, Kelli C.
Erickson, Craig A. http://orcid.org/0000-0003-4512-398X
Article History
Accepted: 7 August 2021
First Online: 7 September 2021
Declarations
:
: The authors declare that they have no interests that compete directly with this work, though Drs. Lamy and Erickson do receive research support from various sources for other work. Dr. Lamy’s current research is supported by OVID Therapeutics and the Simon’s Foundation. Dr. Erickson has received current and/or past research support from the National Institutes of Health, the United States Department of Defense, the United States Centers for Disease Control, the John Merck Fund, Autism Speaks, the Simons Foundation, Cincinnati Children's Hospital Research Foundation, the FRAXA Research Foundation, the National Fragile X Foundation, the Roche Group, Seaside Therapeutics, Novartis, Stalicla, Scioto Bioscience, Janssen, Neuren, Alcobra, and Indiana University School of Medicine. He is a current consultant to Impel, Forge Therapeutics, and Stalicla. He holds equity interest in and is a consultant to Confluence Pharmaceuticals. He is the inventor on intellectual property held by Cincinnati Children's Hospital Research Foundation and Indiana University describing methods for diagnosis and treatment methods in autism spectrum disorder and fragile X syndrome.